A new study found that tirzepatide was more effective than semaglutide in reducing body weight and waist circumference in individuals with obesity but no diabetes. The study was funded by Eli Lilly and registered under the SURMOUNT-5 ClinicalTrials.gov number (NCT05822830). The results were observed at week 72.
Original Source: https://pubmed.ncbi.nlm.nih.gov/40353578/
A recent study has identified cancer-specific peptides that can be presented by human leukocyte antigen class I (HLA-I), providing potential targets for T cell therapy in pancreatic cancer treatment. These…
Current Number of People Receiving Pharmacological Treatment for Mental Disorders #MentalHealth #PublicHealth #CDC #DataAnalysis #Wellbeing A significant portion of Americans receive medical treatment for mental health conditions. In 2020, approximately 16.5% of…
